# An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

> **NCT01323192** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 284 (actual)

## Conditions studied

- Attention-Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** JNS001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01323192
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 284 (ACTUAL)
- **Last updated:** 2013-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01323192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01323192, "An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01323192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*